Abstract
Biosimilars, or generic biologic drugs, are marketed around the world but
still restricted in the U.S. This may soon change, and Kalorama Information
has released this timely study of the market in Europe and other areas in the
world and the possibility of a U.S. Market in the near future. As part of its
research, this Kalorma Information report provides the following:
- Current market size and forecasts for biogenerics in Europe and Rest of
World Markets
- Review of Marketed Biological Drugs with Expired Patents
- Review of Marketed Biological Drugs with Active Patents
- Profiles of the Major Competitors in biogenerics
- Discussion of FDA and EMEA regulatory activity
- Pending U.S. Legislation and Projections for US Markets
- Coverage of Patent Trends, Pricing Trends, Healthcare Spending, IP and
ohter Relevant Issues and Trends
For purposes of study, Kalorama has focused on the market for products which
have lost patent in key markets. Projections were made based on the progress
that is occurring within the generic arena in terms of capabilities, capital,
interest, and development of biopharmaceuticals.
Kalorama has identified the biopharmaceuticals that have lost patent
protection and are likely to be the first products that will be attempted by
generic companies. Some of these products are relatively simple in structure
(by biotech complexity) such as the insulins and human growth hormones, while
others are extremely difficult to process.
There are a number of biopharmaceuticals that are identified as potential
targets for generic development. Many of these biopharmaceutical patents have
expired. Many of these products sport manufacturer sales of over $10 billion,
presenting a ripe opportunity for generic manufacturers. However, because many
of these products demonstrate sales of over $1 billion per year, it is
anticipated that there will considerable resistance from the biotech innovator
companies in allowing generic capitalization and consequently approvals.
The information and analysis presented in this report are based on an
extensive survey of senior management in the biogeneric drug industry.
Background information was obtained from a comprehensive search of published
literature and reports obtained from various government, business, medical
trade, and international journals.
Key information from published literature was used to conduct interviews with
over 42 industry executives and product managers to validate and obtain expert
opinion on current and future trends in the psychotherapeutic industry.
Interviews were also used to confirm and/or adjust market size, as well as in
formulating market projections.
All market data pertains to the world market at the manufacturers' level. Data
are expressed in current U.S. dollars. The geographic scope of the study is
worldwide with particular emphasis on the United States and Europe.
| 
View Cart
